皮肤葡萄糖传感与血糖相比有较短的时间滞后:对低血糖检测和范围内的时间的影响
Khadije Ahmad1, Peter Rule1, Brianna Bañez1
1Laxmi Therapeutic Devices, Goleta, CA, USA.
Journal of diabetes science and technology
|December 9, 2025
概括
一种新的皮肤连续葡萄糖监测仪 (CGM) 与当前皮下CGM相比,显著减少了时间滞后 (τ). 这种提高葡萄糖读数的准确性导致更好的糖尿病管理和更高的时间范围 (TIR).
科学领域:
- 生物医学工程 生物医学工程
- 糖尿病 技术 技术
- 临床研究 临床研究
背景情况:
- 测量皮下组织中的葡萄糖的连续血糖监测器 (CGM) 显示出显著的时间滞后 (τ),可能导致严重的低血糖/高血糖和缩短范围时间 (TIR).
- 皮肤传感提供了一种有希望的方法,可以大大减少这种时间延迟.
研究的目的:
- 为了评估一种新型皮肤CGM传感器的时间滞后动力学.
- 为了比较皮肤CGM与商业CGM (Abbott-Libre 3,Dexcom-G7) 和YSI-葡萄糖分析仪的性能.
- 分析缩短时间延迟对TIR和自动胰岛素输送 (AID) 系统的影响.
主要方法:
- 一项临床研究涉及1型糖尿病 (DM) 的受试者,他们与商业CGM一起使用了新型皮肤CGM.
- 时间滞后动力学是使用两模型建模的,并与已发表的数据进行比较.
- 在UVA1型糖尿病模拟器中,使用in silico比例积分导数 (PID) 控制器评估了时间滞后对TIR的影响.
主要成果:
- 新型皮肤CGM表现出快速的动力学,93%的传感器显示了0-2分钟的t.
- 商业CGM表现出更广泛的t分布 (-10到10+分钟),这表明时间滞后很大.
- 大约10分钟的 τ 缩短显示了对模拟的 AID 系统中胰岛素注射错误和 TIR 分布的深刻影响.
结论:
- 皮肤传感技术实现了近于零的时间延迟,用于血糖监测.
- 这一进步使得DM患者能够安全地设定较低的葡萄糖目标,减少低血糖的恐惧,改善TIR和整体糖尿病控制.
相关概念视频
Hypoglycemia and Glucagon
778
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
778
Oral Hypoglycemic Agents: Glinides
572
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
572
Glucagon-like Receptor Agonists
820
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
820
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
509
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
509
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K


